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Cathepsin-D is a lysosomal aspartyl protease which is expressed in
all tissues. In breast cancer, it was first identified as a 52-kDa
oestrogen-regulated secretory glycoprotein with autocrine mito-
genic activity (Westley and Rochefort, 1979, 1980; Vignon et al,
1986; Rochefort, 1994; Westley and May, 1996). In oestrogen
receptor (ER)-positive breast cancer cells, its gene transcription is
increased by oestrogen and growth factors, whereas in ER-nega-
tive breast cancer cells it is constitutively expressed by an
unknown mechanism. Many biological roles have been attributed
to cathepsin-D (reviewed by Westley and May, 1996), including,
among others: degradation of the extracellular matrix (Briozzo et
al, 1988), increasing cells’ malignant phenotype and metastatic
potential (Garcia et al, 1990), stimulation of (metastatic) cell
proliferation by increasing the local bioavailability of growth-
stimulatory growth factors (Briozzo et al, 1991; Conover and
De Leon, 1994), inactivation of a growth inhibitor (Liaudet et al,
1995), and prevention of apoptosis (Saftig et al, 1995).
In patients with primary breast cancer, overexpression of
cathepsin-D was found to be related to a poor prognosis (Thorpe et
al, 1989; Spyratos et al, 1989), in analogy with observations made
with the serine protease urokinase-type plasminogen activator (uPA),
of which increased activity (Duffy et al, 1988) and antigen level
(Jänicke et al, 1990) have been shown to be associated with a poor
prognosis. The initial studies of Thorpe et al (1989) and Spyratos
et al (1989), using quantitative immunoassays (enzyme-linked
immunosorbent assay, immunoradiometric assay) to assess cytosolic
cathepsin-D levels, have been confirmed by many others employing
the same technique (reviewed by Rochefort, 1994; Westley and May,
1996). However, utilization of other methods to assess cathepsin-D
status, i.e. Western blotting and immunohistochemistry, resulted in
discrepant results (Henry et al, 1990; Tandon et al, 1990; Domagala
et al, 1992, Isola et al, 1993; Ravdin, 1993, Ravdin et al, 1994;
Westley and May, 1996). These conflicting results have been attrib-
uted to the use of different antibodies without standardized quantifi-
cation (Cardiff, 1994; Rochefort, 1996, Westley and May, 1996), a
problem which is not encountered when quantitative immunoassays
on cytosolic extracts are used (Benraad et al, 1992).
Notwithstanding the drawbacks of immunohistochemistry and
contrasting data (Cardiff, 1996; Emmert-Buck, 1996; Rochefort,
1996, Westley and May, 1996), there is evidence that the expres-
sion of cathepsin-D by host stromal cells (Têtu et al, 1993; Joensuu
et al, 1995; O’Donoghue et al, 1995; Nadji et al, 1996), or the
cancer cells (Isola et al, 1993), is associated with prognosis. It has
been suggested that measuring total cathepsin-D levels in tumour
extracts (comprising tumour cells and host cells) has no practical
value (Nadji et al, 1996). This firm conclusion drawn from data
obtained from only 154 patients is surprising. In contrast to
conflicting data obtained with immunohistochemistry, there exists
ample evidence for an independent relationship of poor prognosis
with high cathepsin-D levels measured in breast tumour extracts
(Rochefort, 1994; Westley and May, 1996). This is also true for the
clinically most relevant subset of node-negative patients (Spyratos
et al, 1989; Thorpe et al, 1989; Kute et al, 1992; Foekens et al,
1993, 1996; Westley and May, 1996; Ferrandina et al, 1997).
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In the present definitive study, we have determined cytosolic
cathepsin-D values by IRMA in 2810 patients with primary breast
cancer and have correlated these levels with patient and tumour
characteristics and prognosis.
PATIENTS AND METHODS
Patients and tissues
Inclusion criteria for the 2810 patients from whom tumour or
cytosol samples were stored in our tumour bank (liquid nitrogen)
were: primary diagnosis of breast cancer between 1978 and 1992
(at least 5 years of potential follow-up); no metastatic disease at
diagnosis; no previous diagnosis of carcinoma, with the exception
of basal cell skin carcinoma and cervical cancer stage I; no
evidence of disease within 1 month of primary surgery. In case of
mastectomy after an initial lumpectomy because of residual
disease, the mastectomy is considered as (part of) the primary
treatment. Patients with inoperable T4 tumours and patients who
received neoadjuvant treatment before primary surgery were
excluded. Median age of the patients at the time of surgery (modi-
fied mastectomy, 1502 patients; breast conserving lumpectomy,
1308 patients) was 57 years (range 24–94 years). Radiotherapy
was given to 76% of the patients: on the breast/thoracic wall in
1787 patients and/or on the axilla in 763 patients, and/or on one or
more lymph node areas other than the axilla in 894 patients. None
of the node-negative patients received adjuvant therapy. Of the
1369 node-positive patients, adjuvant chemotherapy (mainly
CMF; cyclophosphamide, methotrexate, 5-fluorouracil) was given
to 451 patients, whereas 206 patients received adjuvant hormonal
therapy either alone (183 patients) or in combination with
chemotherapy (23 patients). All patients were routinely examined
every 3–6 months during the first 5 years of follow-up and once a
year thereafter. Of the 2810 patients, 147 patients (5%) died
without evidence of disease and were censored at last follow-up in
the analysis for relapse-free survival. During follow-up, 1306
(46%) patients showed a relapse and were counted as failures in
the analysis for relapse-free survival. Nine hundred and forty-two
(34%) patients died after a previous relapse. A total of 1089 (147 +
942) were counted as failures in the analysis for overall survival.
The median follow-up period of patients still alive was 88 months
(range 1–207 months). Further characteristics of patients and
tumours are listed in Table 1.
Assay of cathepsin-D, oestrogen receptor (ER) and
progesterone receptor (PgR)
Tumour tissues were stored in (liquid nitrogen) and pulverized in
the frozen state with a microdismembrator following the recom-
mendations of the European Organization for Research and
Treatment of Cancer (EORTC) for processing of breast tumour
tissue for cytosolic ER and PgR determinations (EORTC Breast
Table 1 Relationship between cathepsin-D levels and patient and tumour characteristics
Characteristic Number of Percentage of patients according to
patientsa cathepsin-D content (pmol mg–1 protein)
0–33 > 33–47 > 47–70 > 70 P-value
All patients 2810 25 25 25 25
Age at surgery (years) 0.01b
≤ 40 326 26 27 24 23
40–55 1008 27 24 25 24
56–70 960 23 26 26 25
> 70 516 25 23 24 28
Menopausal status 0.03c
Premenopausal 1112 26 26 24 24
Post menopausal 1698 24 24 25 26
Tumour size 0.0001c
T1 1198 29 24 24 23
T2 1345 21 26 27 27
T3/4 267 26 25 21 27
Nodal status 0.0001c
No 1412 28 27 25 20
N1–3 708 23 25 26 26
N > 3 661 19 21 25 34
Grade 0.1c
Well/moderate 576 27 25 23 25
Poor 1561 23 25 26 26
ER positived < 0.0001b
No 604 28 27 24 21
Yes 2130 24 24 25 27
PgR positived < 0.0001b
No 798 27 25 26 23
Yes 1888 24 24 25 26
aBecause of missing values, the numbers do not always add up to 2810. bP-value for Spearman rank correlation. cP-value for Kruskall–Wallis test, including a
Wilcoxon-type test for trend across ordered groups, when appropriate. dCut-off point used for ER and PgR: 10 fmol mg–1 protein.302 JA Foekens et al
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Cancer Cooperative Group, 1980). The resulting tissue powder
was suspended in EORTC receptor buffer (10 mM dipotassium
hydrogen phosphate buffer, containing 1.5 mM dipotassium
chloride EDTA, 3 mM sodium azide, 10 mM monothioglycerol and
10% v/v glycerol, pH 7.4). The suspension was centrifuged for 30
min at 100 000 ´ g to obtain the supernatant fraction (cytosol). ER
and PgR levels were determined by ligand binding assay or
enzyme immunoassay as described before (Foekens et al, 1989).
The cut-off level used to classify tumours as ER or PgR positive
and negative was 10 fmol mg–1 cytosolic protein.
Cathepsin-D levels were determined in breast tumour cytosols
with a radiometric immunoassay (ELSA-CATH-D; CIS bio inter-
national, Gif-sur-Yvette, France). To enable the assessment of the
between-assay variations (%CV), in each assay run an aliquot of a
pooled breast cancer cytosol sample was analysed. Over a period of
7 years, the between-assay coefficient of variation (CV) was 8.2%.
The within-assay CVs of samples measured in duplicate was 2.9%.
Statistical analysis
The associations of cathepsin-D with other variables were tested
with non-parametric tests: with Spearman rank correlation (rs) for
continuous variables (age, ER, PgR), and the Wilcoxon rank-sum
test or Kruskall–Wallis test, including a Wilcoxon-type test for trend
across ordered groups where appropriate, for categorical variables.
A search for cut-off points to allow analysis of the cathepsin-D as a
categorical variable was considered to be justified after it had been
verified in univariate and multivariate tests for trend using Cox
regression analysis (Cox, 1972) that higher levels of cathepsin-D
were significantly associated with a poor (relapse-free) survival. For
this search, isotonic regression analysis (IRA) with the length of
relapse-free survival as end point (Barlow et al, 1972; Foekens et al,
1994), with modifications, was used. In the modified analysis, the
reference value for the relative relapse rate was set at 1 at the median
cathepsin-D concentration of 47 pmol mg–1 protein. Moreover, IRA
was performed after correction for age and menopausal status,
tumour size, the number of positive lymph nodes, adjuvant therapy,
ER and PgR. In addition, spline regression analysis (Gray, 1992)
was performed to compare the fitted step function of the IRA with a
smooth transformation from the spline regression analysis. Relapse-
free and overall survival probabilities were calculated by the actu-
arial method of Kaplan and Meier (1958). To prevent unreasonable
influence of cathepsin-D outliers in regression analyses, we replaced
values above the 95th and below the 5th percentiles by these values
which were 125.14 and 16.85 pmol mg–1 protein respectively. Both
uni- and multivariate analysis, including tests for interactions, were
performed using the Cox proportional hazard model. The associated
likelihood ratio test was used to test for differences between models
with variables in- and excluded. In the multivariate analyses, the
unknowns for ER/PgR status, and nodal status, were treated as sepa-
rate groups to allow inclusion of all 2810 patients in the final
models. All computations were carried out with the STATA statis-
tical package, release 5.0 (STATA Corp., College Station, TX,
USA). All P-values were two-sided and relate to all available data
unless otherwise indicated.
RESULTS
Levels and associations
The median cathepsin-D level measured with IRMA in breast
cancer cytosols was 47 pmol mg–1 protein (range 0–902 pmol mg–1
protein; mean ± s.d. 58 ± 48 pmol mg–1 protein). Figure 1 shows
the log-normal distribution of cathepsin-D levels in 2810 cytosols.
Table 2 Cox univariate and multivariate analysis of relapse-free and overall survival
Factor Relapse-free survival Overall survival
Univariate Multivariate Relative Univariate Multivariate Relative
P-value P-value relapse ratea P-value P-value death ratea
Age and menopausal status < 0.0001b < 0.0001b < 0.0001b < 0.0001b
Age premenopausalc 0.67 (0.59–0.76) 0.74 (0.63–0.86)
Age post menopausalc 0.92 (0.84–1.00) 1.21 (1.11–1.33)
Post vs. premenopausald 1.44 (1.17–1.78) 1.41 (1.09–1.82)
Tumour size < 0.0001 < 0.0001 < 0.0001 < 0.0001
2–5 cm vs ≤ 2 cm 1.40 (1.23–1.59) 1.43 (1.24–1.65)
> 5 cm vs ≤ 2 cm 1.98 (1.63–2.39) 1.96 (1.60–2.39)
Nodal status < 0.0001 < 0.0001 < 0.0001 < 0.0001
N1–3 vs N0 1.99 (1.70–2.34) 2.08 (1.75–2.47)
N>3 vs N0 3.70 (3.17–4.31) 3.47 (2.94–4.10)
Adjuvant therapy (yes vs no) < 0.0001e < 0.0001 0.62 (0.53–0.72) < 0.0001e 0.002 0.78 (0.66–0.91)
ER/PgR statusf 0.004 0.12 < 0.0001 < 0.0001
High/low vs low/low 0.95 (0.77–1.16) 0.81 (0.66–1.00)
Low/high vs low/low 0.81 (0.61–1.08) 0.65 (0.47–0.89)
High/high vs low/low 0.85 (0.73–0.99) 0.61 (0.52–0.71)
Cathepsin D statusg < 0.0001 < 0.0001 < 0.0001 < 0.0001
Q2 vs Q1 1.27 (1.08–1.50) 1.36 (1.13–1.64)
Q3 vs Q1 1.45 (1.24–1.71) 1.52 (1.26–1.82)
Q4 vs Q1 1.48 (1.26–1.74) 1.56 (1.31–1.87)
aRelative hazard rate (95% confidence interval). In the final multivariate models, all 2810 patients were included. bAge and menopausal status combined. cAge
in decades tested separately for pre- and post-menopausal patients. dPost menopausal as compared with premenopausal. eNode-positive patients only. fHigh vs
low: ³ 10 vs < 10 fmol mg–1 protein. gQ1: 0–33, Q2: > 33–47, Q3: > 47–70 and Q4: > 70 pmol mg–1 protein respectively.Cathepsin-D and breast cancer prognosis 303
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In Table 1, the percentage of tumours with cathepsin-D levels
divided in quarters is shown in relation to patient and tumour char-
acteristics. There was no significant relationship between
cathepsin-D levels and grade of the tumour. Higher levels of
cathepsin-D were found in tumours of older, post-menopausal and
node-positive patients. Moreover, higher cathepsin-D levels were
measured in larger and steroid hormone receptor-positive tumours
(Table 1). The Spearman rank correlation coefficients between
cathepsin-D levels and age (rs = 0.05), and the levels of ER (rs =
0.12) and PgR (rs = 0.11), were very weak albeit statistically
significant because of the large number of samples.
Univariate analysis of relapse-free and overall survival
In univariate Cox regression analysis using log-transformed
cathepsin-D values, increasing levels of cathepsin-D were associ-
ated with poor relapse-free (chi-squared = 57, d.f. = 1, P < 0.0001)
and overall survival (chi-squared = 51, d.f. = 1, P < 0.0001). Also,
after dividing cathepsin-D levels in quarters, higher levels were
associated with an early relapse (chi-squared = 53, d.f. = 3, P <
0.0001) and death (chi-squared = 54, d.f. = 3, P < 0.0001). The
relative relapse rates (including their 95% confidence interval), set
at 1 for tumours containing cathepsin-D levels ranging from 0 to
33 pmol mg–1 protein (quarter 1: Q1), increased from 1.27
(1.07–1.49), via 1.55 (1.32–1.82) to 1.71 (1.46–2.00) for tumours
containing cathepsin-D levels in the second (Q2), third (Q3) and
fourth quarters (Q4) respectively. Similarly, compared with
tumours containing cathepsin-D levels in Q1, the relative death
rates of patients with cathepsin-D levels belonging to Q2, Q3 and
Q4 increased from 1.39 (1.15–1.67), via 1.59 (1.33–1.90) to 1.87
(1.57–2.22). The Kaplan–Meier curves visualizing the 10-year
relapse-free and overall survival probabilities as a function of
cathepsin-D levels in quarters illustrate the increased rates of
relapse and death with increasing levels of cathepsin-D (Figure 2).
At 10 years, the difference in relapse-free survival probability
between patients with the lowest 25% cathepsin-D levels (Q1:
55%  ± 3% relapse-free) compared with the highest 25% cathepsin-
D levels (Q4: 36% ± 3% relapse-free) was 18%. Similarly, at 10
years of follow-up, the difference in overall survival probabilities
between the Q1 and Q4 groups was 20% (Q1: 63% ± 3%, and Q4:
43% ± 3% deaths respectively).
Multivariate analysis of relapse-free and overall
survival
Table 2 shows that the classical prognostic factors, age/
menopausal status, tumour size and the number of positive lymph
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Figure 1 Distribution of cathepsin-D over 2810 human primary breast
tumour cytosols
Figure 3 Isotonic regression analysis for relapse-free survival as a function
of cathepsin-D levels. Expressed are the relative relapse rates as a function
of the level of cathepsin-D with the median of 47 pmol mg–1 protein as
reference value (1.0). Values are corrected for age/menopausal status,
tumour size, the number of positive lymph nodes, adjuvant therapy, ER and
PgR status. Step-function: isotonic regression analysis. Smooth curve: spline
regression analysis. Cathepsin-D values were shrunk at the 5% and 95%
percentiles, with the values below and above set at 16.85 and 125.14
respectively. At both extreme percentiles, the point estimates in the figure
represent 148 patients. Numbers between parentheses indicate the number
of patients grouped by isotonic regression analysis. Arrow indicates position
of cut-off point at 45.2 pmol cathepsin-D mg–1 protein
Figure 2 Actuarial relapse-free (A) and overall survival (B) as a function of
the level of cathepsin-D divided by quartiles. Q1: 0–33, Q2: > 33–47, Q3:
> 47–70, and Q4: > 70 pmol mg–1 protein respectively. Numbers between
parentheses indicate the number of failures/total number of patients in each
group
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nodes, which were strong prognostic factors in univariate analysis,
significantly added to the multivariate models for relapse-free and
overall survival. Adjuvant therapy in node-positive patients was
associated with a favourable prognosis in univariate analysis and,
when included as an indicator variable, also significantly
contributed to both the multivariate models. Steroid hormone
receptor status, which was a significant predictor for a favourable
relapse-free and overall survival in univariate analysis, was an
independent factor in analysis for overall survival only. Grade of
differentiation, which was associated with a poor prognosis in
univariate analysis for both relapse-free and overall survival (both
P < 0.0001), was omitted from the multivariate models because
many values were missing.
The independent predictive effect of cathepsin-D on relapse-
free and overall survival was assessed with Cox multivariate
analysis including age/menopausal status, tumour size, the number
of positive lymph nodes, adjuvant therapy and ER/PgR status.
Corrected for the classical prognostic factors, when used as a cate-
gorical variable divided by quartiles, cathepsin-D significantly
predicted an early relapse (increase in chi-squared: 29, d.f. = 3, P <
0.0001) and death (increase in chi-squared: 29, d.f. = 3, P <
0.0001) (Table 2). When cathepsin-D was added as a log-trans-
formed continuous variable, instead of as a categorical variable to
the multivariate models, similar increases in chi-squared were
observed, confirming its strong independent association with a
poor relapse-free (increase in chi-squared: 29, d.f. = 1, P < 0.0001)
and overall survival (increase in chi-squared: 25, d.f. = 1, P <
0.0001). This similar increase in chi-squared with less degrees of
freedom suggests that cathepsin-D should rather be considered as a
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Figure 4 Actuarial relapse-free survival as a function of cathepsin-D status in subgroups of node-negative (A), node-positive (B), premenopausal (C) and post-
menopausal patients (D). Cathepsin-D-low: cathepsin-D levels < 45.2 pmol mg–1 protein; cathepsin-D-high: cathepsin-D levels ³ 45.2 pmol mg–1 protein. Numbers
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Figure 5 Multivariate analysis for relapse-free survival in subgroups of
patients as a function of cathepsin-D status. Data shown are point estimates
with 95% confidence interval of patients with cathepsin-D tumour levels
³ 45.2 pmol mg–1 protein, compared with values < 45.2 pmol mg–1 protein
(set at 1.0), after correction for age/menopausal status, tumour size, nodal
status, adjuvant therapy, and/or ER/PgR. Numbers between parentheses
indicate the number of patients in each (sub)group. The dotted vertical line
indicates a relative relapse rate of 1.39, which belongs to tumours with
cathepsin-D values ³ 45.2 pmol mg–1 protein in all 2810 patientscontinuous variable instead of as a categorical variable (see also
below). There were no statistically significant interactions
between the classical prognostic factors, or between cathepsin-D
and any of the classical prognostic factors, in analysis for relapse-
free survival.
Assessment of cut-off point for cathepsin-D
In the reported literature, cathepsin-D is almost exclusively
analysed as a dichotomized variable (Westley and May, 1996;
Ferrandina et al, 1997). To enable comparison of our data with
those reported in the literature, and to classify tumours as
cathepsin-D-high and -low, we have searched for an optimized cut-
off point in our cohort of patients. We considered this search justi-
fied because in a test for trend logarithmically transformed
cathepsin-D levels were (independently) associated with a poor
prognosis (see above), and also when analysed as a categorical
variable classified by quartiles (Figure 2, Table 3). For this search,
we have employed isotonic regression analysis (Barlow et al,
1972; Foekens et al, 1994) with the rate of relapse as end point.
The relative relapse rate belonging to the median cathepsin-D
value of 47 pmol mg–1 protein was set at 1. Corrected for age,
menopausal status, tumour size, the number of positive lymph
nodes, adjuvant therapy and ER/PgR status, the results from
isotonic regression analysis showed a stepwise increase in the rate
of relapse with cathepsin-D levels increasing from ≤ 16.9 to
45.2 pmol mg–1 protein. At higher levels of cathepsin-D, the rela-
tive relapse rate was more or less constant (Figure 3). The results
of the isotonic regression analysis match very well with those of
cubic spline regression (Figure 3, solid line). In fact, there is no
clear indication for a cut-off point because the analyses suggest a
continuous increase of the relapse rate for cathepsin-D values up to
± 45 pmol mg–1 protein. However, to allow comparison of our
results with those of others, we have chosen a cathepsin-D level of
45.2 pmol mg–1 protein as a cut-off point to define tumours as
cathepsin-D-high and -low. Using this cut-off point, 53% of the
tumours were classified as cathepsin-D-high and 47% as
cathepsin-D-low.
Subgroup analysis
In subsequent exploratory analyses, we have analysed the associa-
tion of cathepsin-D, used as a dichotomized variable, with relapse-
free survival in clinically relevant subgroups of patients. Figure 4
shows the 10-year relapse-free probability as a function of high
and low cathepsin-D levels in subgroups of node-negative (Figure
4A), node-positive (Figure 4B), premenopausal (Figure 4C) and
post-menopausal patients (Figure 4D). As expected from the
observed lack of interaction between cathepsin-D and the various
classical prognostic parameters in univariate analysis for relapse-
free survival, the prognostic value of cathepsin-D was almost
equally strong in the four subgroups of patients. The relative
relapse rates for tumours with high cathepsin-D levels, compared
with those with low cathepsin-D levels, ranged from 1.42 to 1.57
(Figure 4). This similar prognostic strength of cathepsin-D in the
various subgroups of patients is further illustrated in Figure 5,
showing comparable relative relapse rates as a function of
cathepsin-D status in subgroups of patients, after correction for
age/menopausal status, tumour size, nodal status and steroid
hormone receptor status.
DISCUSSION
In the literature, there is controversy regarding the prognostic
significance of cathepsin-D in primary breast cancer. This dispute
originates from studies using either immunohistochemistry or
Western blotting techniques (Henry et al 1990; Tandon et al, 1990;
Domagala et al, 1992; Isola et al, 1993; Ravdin, 1993; Ravdin et
al, 1994; Cardiff, 1996; Rochefort, 1996). Henry et al (1990)
reported that immunohistochemically assessed cathepsin-D in
tumour cells was associated with a favourable prognosis in node-
positive patients. In contrast, Isola et al (1993) in a study involving
262 node-negative patients showed that tumour cell-associated
cathepsin-D expression was associated with a poor prognosis.
These latter investigators furthermore showed that cathepsin-D
expression in macrophages was not significantly related to prog-
nosis. The opposite, i.e. expression of cathepsin-D by host cells
rather than by the tumour cells is related with a poor prognosis,
was reported in several other studies (Têtu et al, 1993; Joensuu et
al, 1995; O’Donoghue et al, 1995; Nadji et al, 1996). However, in
none of these latter studies was cathepsin-D an independent
prognostic variable.
From many studies in which cathepsin-D status was assessed by
ELISA or IRMA in tumour cytosols, like the present one, there is
agreement between the results of the various studies. They virtu-
ally all show an adverse prognosis with increasing cathepsin-D
levels, in many cases also in multivariate analysis (reviewed by
Rochefort, 1994; Westley and May, 1996). It is, however, not
surprising that different methods give different results.
Measurement of cathepsin-D by IRMA in cytosols will result in an
estimate of the cathepsin-D level originating from tumour cells
and host cells. The advantage of immunohistochemistry is that the
expression of cathepsin-D by the different cell types, such as
tumour cells and host macrophages, can be studied separately.
Various studies have been performed to address the relative contri-
bution of the different cell types responsible for the cathepsin-D
level in tumour cytosols. The cytosolic cathepsin-D level was
shown to correlate well with cathepsin-D expression in cancer
cells (Maudelonde et al, 1992; Remmele and Sauer-Manthey,
1993; Roger et al, 1994). This correlation was found to be stronger
than that between the cytosolic cathepsin-D level and the number
of macrophages in the tumour (Remmele and Sauer-Manthey,
1993; Roger et al, 1994). Also regarding this aspect, there is no
agreement and the reverse has been reported (Razumovic et al,
1997). We fully agree with the statement which has been put
forward previously by Rochefort (1996), ‘one should not mix data
obtained by well-standardized and controlled cytosolic assays with
those obtained by immunohistochemistry using different anti-
bodies without standardized quantification’.
As mentioned above, virtually all studies addressing the prog-
nostic value of cytosolic cathepsin-D level with breast cancer
prognosis show that a high level is associated with a poor relapse-
free and overall survival (reviewed by Westley and May, 1996).
However, there is no consensus with respect to its prognostic value
in node-negative patients. In a recent meta-analysis involving
2690 node-negative patients, it was shown that a high level of
cathepsin-D was associated with a poor relapse-free survival
(Ferrandina et al, 1997). In the present study involving 1412 node-
negative patients, cathepsin-D was also found to be significantly
associated with a poor relapse-free survival, and also in multi-
variate analysis (Figure 5). Moreover, we observed no statistically
significant interaction between cathepsin-D and any of the
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Therefore, there are no reasons to assume that the prognostic value
of cathepsin-D would be different for the various subgroups of
patients. Indeed, the relative relapse rates for patients with high
tumour levels of cathepsin-D, compared with those with low levels
in the various clinically relevant subgroups of patients, were
similar, and their 95% confidence intervals all showed an overlap
(Figure 5).
In most studies in which cathepsin-D level was determined in
cytosols, a lack of significant relationships between cathepsin-D
and classical prognostic factors was reported. Also in the present
study, the relationships of cathepsin-D with older age and post-
menopausal status, larger tumour size, the number of positive
lymph nodes, ER and PgR were weak but statistically significant
because of the large numbers of patients (Table 1). These weak
associations may, thus, have no clinical relevance. However, as
has been discussed by Westley and May (1996), the most impor-
tant question is not whether cathepsin-D relates to other prognostic
factors, but whether cathepsin-D is a prognostic factor in its own
right and is able to predict relapse-free and overall survival. From
many studies (Westley and May, 1996), including the present large
study and a recent meta-analysis (Ferrandina et al, 1996), it is clear
that a high level of cathepsin-D, when measured by IRMA or
ELISA in cytosolic extracts, is strongly associated with a poor
prognosis in patients with primary breast cancer. The IRMA is
convenient, can be quality controlled (Benraad et al, 1992), and
can be performed on the same cytosols which are routinely
prepared for ER and PgR estimations (EORTC Breast Cancer
Cooperative Group, 1980).
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